European Pharmaceuticals Analyst Turner provides an update on hidradenitis suppurativa as competition between NOVN & UCB heats up on an Analyst/Industry conference call to be held on November 11 at 10 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NOVN:
- Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
- EPI Health, MC2 Therapeutics present data highlight WYNZORA technology
- EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
- EPI Health, MC2 Therapeutics announce data from psoriasis survey
- EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®